NCT05884463

18F-FAPI PET Imaging in Pancreatic Adenocarcinoma

18F-FAPI PET/CT and 18F-FDG PET/CT in Patients With Pancreatic Adenocarcinoma : A Prospective, Single-Center, Comparative Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To explore the potential efficacy of 18F-FAPI-04 PET/CT for PDAC tumour staging and compare the results with those obtained using 18F-FDG PET/CT.

Detailed description

Accurate diagnosis and staging are crucial for selecting treatment for patients with pancreatic ductal adenocarcinoma (PDAC). The desmoplastic responses associated with PDAC are often characterised by hypometabolism. Here we investigated 18F-fibroblast activation protein inhibitor (18F-FAPI-04) positron emission tomography/computed tomography (PET/CT) in evaluation of PDAC, and compared the findings with those obtained using (18F)-fluorodeoxyglucose (18F-FDG).

Conditions

• 18F-FAPI
• 18F-FDG
• Pancreas Adenocarcinoma
• Diagnosis
• Staging

Interventions

Type	Name	Description
DRUG	18F-FAPI	Intravenous injection of one dosage of 18F-FAPI.
DRUG	18F-FDG	Intravenous injection of one dosage of 18F-FDG.

Timeline

• Start date: 2021-04-01
• Primary completion: 2023-02-28
• Completion: 2023-02-28
• First posted: 2023-06-01
• Last updated: 2023-06-01

Locations

1 site across 1 country: China